Related Experiment Videos
Adenoviral vectors: systemic delivery and tumor targeting
Nicola K Green1, Leonard W Seymour
1Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, UK. nicky.green@clinpharm.ox.ac.uk
Cancer Gene Therapy
|January 11, 2003
Abstract:
The development of a targeted adenoviral vector, which can be delivered systemically, is one of the major challenges facing cancer gene therapy. The virus is readily cleared from the bloodstream, can be neutralised by pre-existing antibodies, and has a permissive cellular tropism. Clinical studies using the ONYX virus have shown limited efficacy, but there are several hurdles to overcome to achieve an effective tumor-specific systemic therapy. In this review, we have summarized the various strategies used to overcome the limitations of adenoviral-mediated gene delivery.